Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Director · President & CEO | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cellectar Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2036-05-28 | Direct | 250,000 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 250,000 · Balance 250,000 F1: This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026. F2: This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026 |
Filing footnotes · ownership attribution and instrument terms
F1: This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
F2: This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 01:07 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001104659-26-082014 · tm2620095-6_4seq1.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common stock · 250,000 shares Expires 2036-05-28 F1 · date: This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026. F2 · derivative.exercise_date: This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026 Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:05 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseWarrants · Derivative | 26,040 | $0.01 Strike: $2.88 | $260.40 |
DisclosureSEC source: 0001104659-26-058851 · tm2614289-1_4seq1.xml · derivative · entry 2 CARUSO JAMES V · CIK 0001202770 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,076 Underlying: Common Stock · 26,040 shares Expires not disclosed F1 · derivative.expiration_date: Expiration dates are as follows: Tranche A shall have a one-year term from the date of stockholder approval; Tranche B shall have a two-year term from the date of stockholder approval; Tranche C shall have a five-year term from the date of stockholder approval. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:05 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 8,680 | $2.88 | $24,998.40 |
DisclosureSEC source: 0001104659-26-058851 · tm2614289-1_4seq1.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,318 Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 12:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseWarrants · Derivative | 10,000 | $0.01 Strike: $5.25 | $100.00 |
DisclosureSEC source: 0001104659-25-065573 · tm2519819-3_4seq1.xml · derivative · entry 2 CARUSO JAMES V · CIK 0001202770 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-07-02 Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 12:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 10,000 | $4.99 | $49,900.00 |
DisclosureSEC source: 0001104659-25-065573 · tm2519819-3_4seq1.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,638 F1 · balance_after: This number has been adjusted for the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 900,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001104659-25-014730 · tm256830-1_4seq1.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2035-02-14 F1 · derivative.exercise_date: This option shall vest over a period of three years from February 14, 2025, with 1/3 vesting on the first anniversary of February 14, 2026 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of February 14, 2026. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 900,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001104659-24-072889 · tm2417520-9_4seq1.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2033-12-15 F1 · date: This option was contingently granted on December 15, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest over a period of three years from December 15, 2023, with 1/3 vesting on the first anniversary of Decembner 15, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of Decembner 15, 2023. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon Stock | 40,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-125483 · tm2332764-1_4seq1.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,236 Read SEC document |
| June 23, 2023 Filed Dec 13, 2023 01:04 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 261,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-23-125483 · tm2332764-1_4seq1.xml · derivative · entry 2 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2033-01-17 F1 · date: This option was contingently granted on January 16, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2023 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 23, 2023. Because January 16, 2023 was a federal holiday, the option was priced on the following trading day. F2 · derivative.exercise_date: This option shall vest over a period of three years from January 17, 2023, with 1/3 vesting on the first anniversary of January 17, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of January 17, 2023. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 23:34 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 261,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001104659-23-004700 · tm233841-2_4seq1.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2033-01-17 F1 · derivative.exercise_date: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:05 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 1,419,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001104659-22-008277 · tm224689-1_4seq1.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419,000 Underlying: Common Stock · 1,419,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:45 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleSeries A Warrants · Derivative | 46,948 | $0.19 Strike: $30.40 | $8,718.24 |
DisclosureSEC source: 0001104659-21-032850 · tm218888d3_4seq1.xml · derivative · entry 3 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,694 shares Expires 2021-04-20 F2 · derivative.exercise_price: Ten warrants are convertible into one share of Cellectar's common stock at an exercise price of $30.40 per share of common stock. F1 · shares: Mr. Caruso used the proceeds of the sale of the Series A Warrants, which expire in April 2021, to purchase shares of Cellectar's common stock. F2 · derivative.underlying_shares: Ten warrants are convertible into one share of Cellectar's common stock at an exercise price of $30.40 per share of common stock. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:45 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 1,600,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-21-032850 · tm218888d3_4seq1.xml · derivative · entry 2 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600,000 Underlying: Common Stock · 1,600,000 shares Expires 2031-03-04 F3 · derivative.exercise_date: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:45 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 5,100 | $1.70 | $8,658.78 |
DisclosureSEC source: 0001104659-21-032850 · tm218888d3_4seq1.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,401 F1 · shares: Mr. Caruso used the proceeds of the sale of the Series A Warrants, which expire in April 2021, to purchase shares of Cellectar's common stock. Read SEC document |
| December 28, 2020 Filed Dec 28, 2020 21:31 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 37,037 | $1.35 | $49,999.95 |
DisclosureSEC source: 0001104659-20-139787 · tm2039438d3_4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,301 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:07 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseSeries H Warrants · Derivative | 10,870 | $0.01 Strike: $1.21 | $108.70 |
DisclosureSEC source: 0001104659-20-070837 · tm2022064d2_4.xml · derivative · entry 2 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,870 Underlying: Common Stock · 10,870 shares Expires 2025-06-05 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:07 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock | 21,740 | $1.15 | $24,892.30 |
DisclosureSEC source: 0001104659-20-070837 · tm2022064d2_4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,264 Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon stock | 100,000 | $2.71 | $271,000.00 |
DisclosureSEC source: 0001104659-20-010608 · tm206696d1_4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Common stock grant that vests in equal annual increments on February 3, 2021, February 3, 2022, and February 3, 2023. Read SEC document |
| February 03, 2020 Filed Mar 5, 2020 21:01 UTC Amendment | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001104659-20-029693 · tm2011832d3_4a.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-03 F1 · shares: This Form 4/A is being filed to correct a Form 4 filed on February 4, 2020, in which the stock option grant was reported as a common stock grant. The underlying value of the award remains unchanged. F2 · derivative.exercise_date: Stock options vest in equal annual increments on February 3, 2021, February 3, 2022, and February 3, 2023. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:17 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001144204-19-002085 · tv511256_4.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 23:23 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | PurchaseCommon Stock, par value $0.00001 per share | 1,000 | $2.28 | $2,282.00 |
DisclosureSEC source: 0001144204-18-062710 · tv508310_4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,354 Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:47 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053874 · tv504837_form4.xml · derivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 70,950 shares, which vest as to all shares on the first anniversary of the grant date, and a contingent grant of 79,050 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest over a period of three years from the grant date, vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | SaleCommon Stock | 34,000 | $1.20 | $40,704.80 |
DisclosureSEC source: 0001144204-18-014636 · tv488453_4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,548 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2017 to satisfy tax withholding obligations upon vesting of restricted stock. F2 · price: The price reported in Column 4 of Line 1 with respect to the 34,000 shares sold on March 12, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.26. The Reporting Person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in Footnote (2) to this Form 4. Read SEC document |
| April 18, 2017 Filed Apr 20, 2017 22:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-021329 · v464724_form4.xml · nonDerivative · entry 1 CARUSO JAMES V · CIK 0001202770 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,548 F1 · shares: Common stock grant that vests in equal annual increments on March 2, 2018, March 2, 2019, and March 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.